Fairvalue-Calculator Fairvalue-Calculator
EN DE

Eupraxia Pharmaceuticals Inc (EPRX) Fair Value & Analysis

Healthcare · US · Market cap $423M

Price$6.39
Fair Value$5.65
Upside-11.6%
Quality92/100
Evidence: Low Range $4.24 – $7.06

Fair value as of: Jun 24, 2026

Analysis

Eupraxia Pharmaceuticals Inc (EPRX) currently trades at $6.39, while our model-based Fair Value estimate is $5.65 — implying the stock looks roughly 11.6% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Eupraxia Pharmaceuticals Inc (EPRX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $5.65 versus a price of $6.39 — about −12% (overvalued). Model-based estimate, not financial advice.
What is the fair value of EPRX?
Our 21-model fair value for Eupraxia Pharmaceuticals Inc is $5.65 (as of Jun 24, 2026), built from audited fundamentals. The current price is $6.39.
What is the quality score of EPRX?
Eupraxia Pharmaceuticals Inc has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.